Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer

Vogel, Ulla; Laros, Imke; Jacobsen, Nicklas Raun; Thomsen, Birthe Lykke; Bak, Helle; Olsen, Anja; Bukowy, Zuzanna; Wallin, Håkan; Overvad, Kim; Tjønneland, Anne; Nexø, Bjørn A.; Raaschou-Nielsen, Ole

doi:10.1016/j.mrfmmm.2003.11.001

Cited by 95 publications

(84 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This exceptional type of gene overlap was conserved in mouse and even in the yeast ERCC1 homolog, RAD10, suggesting an important biologic function of this region (19q13.2-q13.3). Besides, haplotypes in this region have been found associated with increased cancer risk [61][62][63][64][65]. Although we have found an association between MPM and a XRCC1 haplotype and a cumulative of XRCC1 and ERCC1 variants, we have not observed an association with ERCC1 haplotypes.…”

Section: Discussioncontrasting

confidence: 78%

XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case–control study

Betti

Ferrante

Padoan

et al. 2011

Mutation Research/Fundamental and Molecular Mechanisms of Mutag

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 78%

XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case–control study

Betti

Ferrante

Padoan

et al. 2011

Mutation Research/Fundamental and Molecular Mechanisms of Mutag

View full text Add to dashboard Cite

“…This region seems to be candidate for susceptibility to basal cell carcinoma (25,28) and postmenopausal breast cancer before the age of 55 years (30); in particular, the most significant results refer to the association with the polymorphisms in the RAI gene. Previous studies have found markers in XPD located near RAI to be associated with the development of melanoma, glioma, and lung cancer (24,27,55,56), thus, it is possible that this limited region is important for other cancers as well. On the other hand, further studies are needed to clarify whether the same haplotype could have different roles in different cancers as it seems to be suggested by the rapidly accumulating data on single SNPs.…”

Section: Ercc1-19007mentioning

confidence: 99%

Polymorphisms/Haplotypes in DNA Repair Genes and Smoking: A Bladder Cancer Case-Control Study

Matullo

Guarrera

Sacerdote

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

113

View full text Add to dashboard Cite

show abstract

“…32 P-postlabeling) DNA was purified as described previously 15 from WBC sampled on enrolment in the cohort. After isolation, the DNA was precipitated with ice-cold 96% ethanol (2 vol.)…”

Section: Analysis Of Bulky Dna Adduct (mentioning

confidence: 99%

Bulky DNA adducts as risk indicator of lung cancer in a Danish case‐cohort study

Bak

Autrup

Thomsen

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Little is known of the predictive value of the levels of DNA adducts in terms of cancer risk. We examined the association between bulky DNA adducts and risk of lung cancer in a population-based cohort, comprising of 25,717 men and 27,972 women aged 50-64 years at entry. We included 245 cases (137 men and 108 women) with lung cancer and a comparison group of 255 individuals (137 men and 118 women), matched on sex, age and smoking duration. Bulky adducts in white blood cells collected at enrolment and stored at 2150°C were analyzed by 32 P-postlabeling method, using the butanol enrichment procedure. The median level of bulky DNA adducts was 0.196 adduct/10 8 nucleotides (5-95 percentiles: 0.094-0.595) among current smokers who were later diagnosed with lung cancer and 0.163 adduct/10 8 nucleotides (5-95 percentiles: 0.091-0.455) among current smokers in the comparison group. The smoking adjusted incidence rate ratios (IRR) for lung cancer in relation to one log unit (natural logarithm) difference in adduct levels were 1.22 (95% CI 0.85-1.74), 1.33 (95% CI 0.89-1.98) and 0.76 (95% CI 0.39-1.47) among all, current and former smokers, respectively. Current smokers with bulky DNA adduct levels above the median had a significant higher lung cancer rate than those with adduct levels below the median (IRR 5 1.61; 95% CI 1.04-2.49). The results are compatible with previous studies, suggesting a slightly higher risk of lung cancer with higher levels of adducts among smokers. Our results indicate that bulky DNA adducts may have a weak association with lung cancer risk. ' 2005 Wiley-Liss, Inc.

show abstract

Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer

Cited by 95 publications

References 20 publications

XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case–control study

XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case–control study

Polymorphisms/Haplotypes in DNA Repair Genes and Smoking: A Bladder Cancer Case-Control Study

Bulky DNA adducts as risk indicator of lung cancer in a Danish case‐cohort study

Contact Info

Product

Resources

About